Archer Materials (ASX:AXE) is advancing into the feasibility stage the development of the graphene field effect transistor (gFET) sensors for its Biochip, according to a Thursday filing with the Australian bourse.
The company built a dataset of the sensor's performance to advance the feasibility development of the Biochip for its application in blood potassium testing for chronic kidney disease, the filing said.
Archer Materials developed an initial electrical conditioning procedure, which sets individual gFETs to a state of high repeatability. This conditioning resulted in a tenfold improvement in voltage sweeping repeatability, directly enhancing the accuracy of potassium measurements, per the filing.
The company has also completed a round of benchmarking experiments with collaborators at RMIT University to further validate the performance entitlements of gFET sensors.
Archer Materials shares rose almost 2% in recent Friday trade.
Price (AUD): $0.31, Change: $+0.01, Percent Change: +1.64%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.